Program
Fluticasone
Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.
Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 580 open or running | phase 4since Feb 1, 2005 | Feb 1, 2005 | none ahead |
| Respirent Pharmaceuticalsits history only | 182 open or running | phase 3since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Teva Pharmaceutical Industriesits history only | 140 open or running | phase 4since Dec 11, 2020 | Nov 22, 2011 | none ahead |
| Viatrisits history only | 130 open or running | phase 4since Dec 16, 2016 | Nov 21, 2006 | none ahead |
| Optinose USits history only | 101 open or running | phase 3since Jun 13, 2012 | Jun 13, 2012 | Mar 31, 2028phase 3 · NCT06850805 |
| Mundipharmaits history only | 60 open or running | phase 4since Jun 15, 2015 | Oct 14, 2009 | none ahead |
| SkyePharmaits history only | 50 open or running | phase 3since Oct 27, 2006 | Oct 27, 2006 | none ahead |
| Eurofarma Laboratoriosits history only | 31 open or running | phase 3since Sep 14, 2010 | Sep 14, 2010 | Aug 2028phase 3 · NCT06234345 |
| Merckits history only | 30 open or running | phase 2since Oct 5, 2006 | Oct 5, 2006 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 5, 2016 | Jan 5, 2016 | none ahead |
| Intech Biopharmits history only | 20 open or running | phase 1since Jun 2, 2015 | Jun 2, 2015 | none ahead |
| Nicox Ophthalmicsits history only | 20 open or running | phase 2since Apr 19, 2019 | Apr 19, 2019 | none ahead |
| Organonits history only | 20 open or running | phase 4since Oct 30, 2008 | Oct 30, 2008 | none ahead |
| Pfizerits history only | 20 open or running | phase 1since Sep 21, 2009 | Sep 21, 2009 | none ahead |
| Ciplaits history only | 10 open or running | phase 3since Dec 26, 2017 | Dec 26, 2017 | none ahead |
| Fougera Pharmaceuticalsits history only | 10 open or running | phase 4since Oct 16, 2007 | Oct 16, 2007 | none ahead |
| Glenmark Pharmaceuticals Ltd. Indiaits history only | 10 open or running | phase 3since May 2, 2022 | May 2, 2022 | none ahead |
| HALEON | 11 open or running | phase 4since Aug 31, 2026 | Aug 31, 2026 | Dec 2026phase 4 · NCT07817134 |
| Kindeva Drug Deliveryits history only | 10 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| Libbs Farmacêutica LTDAits history only | 10 open or running | phase 3since Apr 1, 2020 | Apr 1, 2020 | none ahead |
| Mannkindits history only | 10 open or running | phase 1since May 5, 2008 | May 5, 2008 | none ahead |
| Neotheticsits history only | 10 open or running | phase 2since Oct 16, 2012 | Oct 16, 2012 | none ahead |
| ORAits history only | 10 open or running | phase 4since Sep 19, 2011 | Sep 19, 2011 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 10 open or running | phase 1since Mar 21, 2012 | Mar 21, 2012 | none ahead |
Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of HALEON only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 31, 2026First study: phase 4 study in Rhinitis, Allergic, PerennialFirst studyNCT07817134 · 16 planned · Canada
Ahead
- Dec 2026Primary completion: phase 4 study in Rhinitis, Allergic, PerennialNCT07817134
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study HALEON leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07817134Rhinitis, Allergic, Perennial · Canada | 4 | Not yet recruiting | Dec 2026 | 16 |
How it is read
Names in the registry
- “Fluticasone Propionate”, 17 entries
- “Fluticasone propionate”, 13 entries
- “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
- “fluticasone propionate”, 7 entries
- “fluticasone propionate/salmeterol”, 7 entries
Codes read as this program: NCX4251, FP100.
Conditions, from the studies’ own filings
- Asthma, 84 studies
- Pulmonary Disease, Chronic Obstructive, 18 studies
- Rhinitis, Allergic, Seasonal, 11 studies
- Rhinitis, Allergic, 9 studies
- Rhinitis, Allergic, Perennial, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.